Clinical pharmacists participated in the disease and etiology investigation, demonstration, summary of etiological drugs and treatment process of a case of multi-factorial drug-induced liver injury (DILI), provided pharmaceutical care for the patient, and put forward medication recommendations. The relevant drugs were stopped, and medication education and warnings were given. After 10 days of treatment, the patient's condition and liver biochemical indicators improved significantly and discharged from the hospital. After 2 months of follow-up, the liver function indexes of the patients returned to normal. The report of this case indicated that the clear identification of the etiology and drugs of DILI was very important, which was related to the ultimate medical quality and life safety. Reporting DILI, especially DILI related to traditional Chinese medicine, should be standardized and reasonable.

1. 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 实用肝脏病杂志, 2017, 20(2): 1-18.DOI: 10.3969/j.issn.1672- 5069.2017.02.039.

2. 中华中医药学会肝胆病分会, 中华中医药学会中成药分会. 中草药相关肝损伤临床诊疗指南[J]. 临床肝胆病杂志, 2016, 32(5): 835-843. DOI: 10.3969/j.issn.1001- 5256.2016.05.003.

3. Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland Chi-na[J].Gastroenterolgy, 2019, 156: 2230-2241. DOI: 10.1053/j.gastro.2019.02.002.

4. 冉姗, 方忠宏, 黄海茵, 等. 中药药物性肝损伤报告中存在的问题及建议[J]. 中医杂志, 2021, 62(7): 581-584.[Ran S, Fang ZH, Huang HY, et al. Problems and suggestions in the report of liver injury caused by traditional Chinese medicine[J]. Journal of Traditional Chinese Medicine, 2021, 62(7): 581-584.] DOI: 10.13288/j.11-2166/r.2021.07.007.

5. 蒋淼, 方忠宏, 刘玉娟, 等. 药(含中药)源性肝损伤的病因溯源[J]. 北京中医药大学学报, 2019, 42(2): 149-159. [Jiang M, Fang ZH, Liu YJ, et al. Cause of drug-induced liver injury (including Chinese medicinals)[J]. Journal of Beijing University of Traditional Chinese Medicine, 2019, 42(2): 149-159.] DOI: 10.3969/j.issn. 1006-2157.2019.02.011.

6. 姜华侨, 王飞, 吕小群, 等. 1例药源性肝损伤的病因药物鉴别报告[J]. 中医杂志, 2020, 61(9): 824-826. [Jiang HQ, Wang F, Lyu XQ, et al. Etiology and drug identification of a case of drug-induced liver injury[J]. Journal of Traditional Chinese Medicine, 2020, 61(9): 824-826.] DOI: 10.13288/j.11-2166/r.2020.09.022.

7. 中华医学会, 消化系统疾病基层诊疗指南编写专家组. 药物性肝损伤基层诊疗指南(2019年)[J].中华全科医师杂志, 2020, 19(10): 868-875. DOI: 10.3760/cma.j.cn114798-20200812-00900.

8. Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests[J]. Postgrad Med J, 2016, 92(1086): 223-234. DOI: 10.1136/postgradmedj-2015-133715.

9. Cai X, Cai H, Wang J, et al. Molecular pathogenesis of acetaminophen-induced liver injury and its treatment options[J]. J Zhejiang Univ Sci B, 2022, 23(4): 265-285. DOI: 10.1631/jzus.B2100977.

10.中国药典2020年版. 一部[S]. 2020: 184.

11.Li C, Rao T, Chen X, et al. HLA-B*35: 01 allele is apotential biomarker for predicting Polygonum multi-florum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357. DOI: 10.1002/hep.30660.

12.葛斐林, 牛明, 韩紫欣, 等. 白鲜皮制剂相关肝损伤的药物流行病学特征分析[J]. 中国中药杂志, 2019, 44(5): 1048-1052. [Ge FL, Niu M, Han ZX, et al. Analysis of epidemiological characteristics of drug induced liver injury associated with Baixianpi Preparations[J]. China Journal of Chinese Materia Medica, 2019, 44(5): 1048-1052.] DOI: 10.19540/j.cnki.cjcmm.20181217.001.

13.葛斐林,肖小河,王伽伯,等.中药药物性肝损伤评价方法及风险因素研究进展[J].中国现代中药, 2019, 21(3): 284-290. [Ge FL, Xiao XH, Wang KB, et al. Research progress in evaluation methods and risk factors for Chinese medicines-induced liver injury[J]. Mod Chin Med, 2019, 21(3): 284-290.] DOI: 10.13313 /j.issn.1673-4890.20180925002.

14.何婷婷, 王丽苹, 任璐彤, 等. 中西药肝损伤临床及病理特征分析[J]. 肝脏, 2021, 26(9): 962-967.[He TT, Wang LP, Ren LT, et al. Analysis of clinical and pathological characteristics of liver injury induced by Chinese and western medicine based on integrated evidencechain[J]. Chinese Hepatology, 2021, 26(9): 962-967.] DOI: 10.14000/j.cnki.issn.1008-1704.2021.09.006.

15.林云霞, 何晓彬. 药物性肝损伤的临床特点及危险因素分析[J]. 临床肝胆病杂志, 2018, 34(6): 1237-1241. [Lin YX, He XB. Clinical features of drug-induced liver injury and related risk factors[J]. J Clin Hepatol, 2018, 34(6): 1237-1241.] DOI: 10.3969 /j.issn.1001- 5256.2018.06.021.

16.中华人民共和国国家卫生健康委员会. 质子泵抑制剂临床应用指导原则(2020年版)[J].中国实用乡村医生杂志, 2021, 28(1): 1-9. DOI: 10.3969/j.issn.1672-7185. 2021.01.001.

17.万瑞融, 黄振光, 张宏亮, 等. 原发性肾病综合征患者的药学监护要点[J]. 中国药师, 2014, 17(8): 1380-1382. [Wan RR, Huang ZG, Zhang HL, et al. Pharmaceutical care for patients with primary nephrotic syndrome[J]. China Pharmacist, 2014, 17(8): 1380-1382.] DOI: 10.3969/j.issn.1008-049X.2014.08.045.

18.中国肝病科相关专家小组. 多烯磷脂酰胆碱在肝病临床应用的专家共识[J]. 中华实验和临床感染病杂志(电子版), 2017, 11(4): 313-319. DOI: 10.3877/cma.j.issn.1674-1358.2017.04.001.

19.张春梅,周俊卿.静脉滴注注射用丁二磺酸腺苷蛋氨酸溶剂使用不当致局部疼痛、红肿2例[J].临床合理用药杂志, 2016, 9(19): 128. [Zhang CM, Zhou JQ. 2 cases of local pain, redness and swelling caused by improper use of intravenous infusion of adenosine methionine succinate[J]. Chin J of Clinical Rational Drug Use, 2016, 9(19): 128.] DOI: 10.15887/j.cnki.13-1389/r.2016.19.073.

20.朱晶晶,陈静,金慧,等.注射用丁二磺酸腺苷蛋氨酸致过敏性休克1例[J].中国药师, 2021, 24(11): 2071-2072. [Zhu JJ, Chen J, Jin H, et al. Anaphylactic shock caused by adenosine succinate for injection: a case report[J]. China Pharmacist, 2021, 24(11): 2071-2072.] DOI: 10.19962/j.cnki.issn1008-049X.2021.11.023.